WE PROSPECTIVELY STUDIED 712 consecutive patients during a 1-year period who presented
with amnesia or loss of consciousness after nonpenetrating head trauma and who had …

Objective Friedreich ataxia (FA) is a progressive genetic neurodegenerative disorder with
no approved treatment. Omaveloxolone, an Nrf2 activator, improves mitochondrial function, …

Objective: To make evidence-based recommendations regarding management of tardive
syndromes (TDS), including tardive dyskinesias (TDD), by addressing 5 questions: 1) Is …

… Zesiewicz has served as a clinical advisor for Steminent Biotherapeutics; has received
travel reimbursement from the Department of Neurology at University of Southern Florida; has …

Essential tremor (ET) is one of the most common movement disorders in the world. Despite
this, only one medication (propranolol) is approved by the Food and Drug Administration (…

In clinical trials for patients with Parkinson's disease (PD) with motor fluctuations, efficacy is
generally ascribed to an intervention if motor function is significantly improved or if “off” time …

Manganese intoxication and chronic liver failure are associated with strikingly similar clinical,
imaging, and pathological abnormalities. As manganese is primarily cleared by the liver, …

Objective: To make evidence-based recommendations regarding restless legs syndrome (RLS)
management in adults. Methods: Articles were classified per the 2004 American …

Background: The objective of this study was to determine the reliability of a new scale for
the clinical assessment of essential tremor. The Essential Tremor Rating Assessment Scale …

Background MOXIe was a two‐part study evaluating the safety and efficacy of omaveloxolone
in patients with Friedreich's ataxia, a rare, progressive neurological disease with no …